Stock A145020 HUGEL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hugel, Inc.

Equities

A145020

KR7145020004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
211,500 KRW -4.30% Intraday chart for Hugel, Inc. +1.20% +41.57%
03-27 Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. CI
03-27 Hugel, Inc. authorizes a Buyback Plan. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,342,298 2,352,299 1,864,449 1,597,992 1,675,393 2,242,856 - -
Enterprise Value (EV) 2 860 1,843 1,406 1,219 1,675 1,800 1,723 1,803
P/E ratio 37.5 x 56.2 x 33 x 29.7 x 18.8 x 22.7 x 17.6 x 14 x
Yield - - - - - - - -
Capitalization / Revenue 6.56 x 11.1 x 7.61 x 5.67 x 5.24 x 5.85 x 5.05 x 4.5 x
EV / Revenue 4.2 x 8.73 x 5.74 x 4.33 x 5.24 x 4.7 x 3.88 x 3.61 x
EV / EBITDA 11.1 x 20.8 x 12.6 x 10.6 x 12.7 x 11.1 x 8.67 x 7.36 x
EV / FCF 13.3 x 32.2 x 22.7 x 25.2 x - 26 x 18.8 x 24 x
FCF Yield 7.52% 3.11% 4.41% 3.96% - 3.84% 5.33% 4.16%
Price to Book 2.37 x 3.15 x 2.41 x 2.03 x - 2.73 x 2.39 x 2 x
Nbr of stocks (in thousands) 10,126 12,526 12,146 11,846 11,214 10,914 - -
Reference price 3 132,565 187,800 153,500 134,900 149,400 205,500 205,500 205,500
Announcement Date 12/03/20 09/02/21 10/02/22 09/02/23 14/02/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 204.6 211 245.2 281.7 319.7 383.3 444.5 498.8
EBITDA 1 77.57 88.76 111.5 115.4 131.6 161.5 198.8 245
EBIT 1 68.09 78.21 97.14 102.5 117.8 148.7 185 227.9
Operating Margin 33.28% 37.06% 39.62% 36.39% 36.86% 38.78% 41.62% 45.69%
Earnings before Tax (EBT) 1 69.73 81.7 89.01 66.51 132.8 147.8 189.5 221.2
Net income 1 44.61 51.87 57.52 57.66 92.3 106.1 136.2 164.1
Net margin 21.81% 24.58% 23.46% 20.47% 28.87% 27.69% 30.65% 32.91%
EPS 2 3,532 3,344 4,658 4,545 7,934 9,068 11,698 14,633
Free Cash Flow 3 64,701 57,325 62,061 48,272 - 69,220 91,765 75,000
FCF margin 31,627.96% 27,164.44% 25,315.05% 17,137.58% - 18,057.12% 20,644.5% 15,037.5%
FCF Conversion (EBITDA) 83,406.25% 64,581.67% 55,680.25% 41,840.33% - 42,865.85% 46,167.85% 30,608.74%
FCF Conversion (Net income) 145,029.21% 110,517.41% 107,903.34% 83,717.39% - 65,218.98% 67,352.37% 45,699.24%
Dividend per Share 2 - - - - - - - -
Announcement Date 12/03/20 09/02/21 10/02/22 09/02/23 14/02/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 55.79 61.01 64.9 67.4 70.68 85.49 64.38 81.56 84.82 88.94 78.98 91.28 109.8 106.8
EBITDA 1 - - - - - 32.82 21.88 31.38 37.69 40.34 28.5 41 45.5 46.5
EBIT 1 21.35 19.74 24.99 22.32 24.77 31.17 18.5 27.98 34.55 36.79 26.75 34.02 45.9 43.2
Operating Margin 38.27% 32.35% 38.5% 33.12% 35.05% 36.46% 28.74% 34.31% 40.74% 41.36% 33.87% 37.28% 41.79% 40.46%
Earnings before Tax (EBT) 1 28.4 11.42 22.14 23.16 31.94 -12.58 24.28 30.87 53.65 24.01 29.3 30.2 38.2 46.1
Net income 1 20.24 3.717 14.98 14.78 25.76 2.143 16.38 21.11 39.39 15.42 22.3 23 29.2 35.2
Net margin 36.28% 6.09% 23.08% 21.93% 36.45% 2.51% 25.43% 25.88% 46.44% 17.34% 28.24% 25.2% 26.59% 32.97%
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 10/11/21 10/02/22 11/05/22 10/08/22 10/11/22 09/02/23 10/05/23 09/08/23 13/11/23 14/02/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 482 509 458 379 - 442 520 440
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 2 64,701 57,325 62,061 48,272 - 69,220 91,765 75,000
ROE (net income / shareholders' equity) 6.25% 5.81% 7.58% 7% - 13.2% 14.7% 15%
ROA (Net income/ Total Assets) 4.92% 4.54% 5.87% 5.33% - 9.94% 11% 11.9%
Assets 1 906.5 1,143 979.4 1,082 - 1,068 1,242 1,379
Book Value Per Share 3 55,845 59,612 63,708 66,477 - 75,322 85,975 102,684
Cash Flow per Share 3 5,330 5,917 6,606 6,817 - 8,086 10,762 -
Capex 1 12.3 17 23.9 33 - 30 27.6 27
Capex / Sales 6.01% 8.04% 9.74% 11.7% - 7.82% 6.21% 5.41%
Announcement Date 12/03/20 09/02/21 10/02/22 09/02/23 14/02/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hugel, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
205,500 KRW
Average target price
218,778 KRW
Spread / Average Target
+6.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
HUGEL, INC. Stock Hugel, Inc.
+41.57% 1.67B
CSL LIMITED Stock CSL Limited
-3.93% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-17.50% 31.47B
UCB Stock UCB
+54.44% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-12.79% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-15.38% 11.89B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.84B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A145020 Stock
  4. Financials Hugel, Inc.